HIV reduces anti-TB drug concentrations
HIV reduces anti-TB drug concentrations
A study published in the Aug. 15 Annals of Internal Medicine confirms reports suggesting that HIV leads to poor absorption of anti-tuberculosis drugs, potentially causing increased risk of drug resistance and incomplete treatment.
Researchers at the University of Ottawa in Ontario evaluated the pharmokinetics of frequently used anti-TB drugs in HIV-positive patients at different stages of disease. The results were compared to drugs given to healthy patients.
The findings showed that drug levels for isoniazid, rifampin, and pyrazinamide were altered by HIV infection. The researchers found that, compared with the control group, HIV-positive patients showed reductions in total system drug exposure of 32% for rifampin and 24% for pyrazinamide.
"Reduced total drug exposure to rifampin and pyrazinamide was associated with D-xylose malabsorption in persons with HIV infection or AIDS. Peak drug exposure to isoniazid was lower in patients with diarrhea," the authors write.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.